<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137019</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMA A19/10</org_study_id>
    <nct_id>NCT01137019</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Peter Barlis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosensors International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Hospital, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use a high-resolution intracoronary imaging modality, called
      optical coherence tomography (OCT) to examine two different types of coronary artery stents
      used to treat patients with coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of coronary stents has significantly improved the safety and efficacy of
      percutaneous coronary intervention (PCI) compared to balloon angioplasty alone. Nevertheless,
      restenosis is still encountered in 20 to 40% of coronary lesions after implantation of bare
      metal stents, inferring frequent repeat revascularization procedures with a negative impact
      on quality of life and health care expenditures. Drug-eluting stents (DES), with their
      controlled release of therapeutic agents, have significantly reduced the rate of major
      adverse cardiac events (MACE) following coronary stent implantation, primarily by a reduction
      in restenosis and target lesion revascularization.

      Optical coherence tomography (OCT) is an optical analogue of intravascular ultrasound (IVUS):
      it uses an infrared light source (wavelength 1310nm) and measures the backscatter of light in
      a technique similar to conventional ultrasound. With this technique a resolution up to 10μm
      in-vivo has been reported, a far better level of resolution compared with IVUS. Optical
      coherence tomography has been used in vivo and has detected early atherosclerotic plaques
      previously not visualised by IVUS. Segments with strut malapposition and the presence or
      thickness of neointimal hyperplasia can also be more accurately assessed with OCT compared
      with IVUS.

      The present study will utilize the imaging capabilities of OCT to assess stent strut
      malapposition and tissue coverage in two different types of DES. The biolimus-eluting stent
      eludes biolimus from a biodegradable polylactic acid polymer on the abluminal surface of a
      stainless steel stent. This stent will be compared in a randomized fashion to the permanent
      polymer based everolimus-eluting coronary stent made of cobalt chromium alloy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of stent strut malapposition</measure>
    <time_frame>0 Days</time_frame>
    <description>Apposition will be examined immediately following stent implantation following angiographic optimization of stent deployment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of stent strut tissue coverage</measure>
    <time_frame>At follow-up (one of either 3, 6, 12 or 15 months)</time_frame>
    <description>Subjects will be randomized to follow-up at either one of the time points post stenting (3, 6, 12 or 15 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus-eluting stent</intervention_name>
    <description>The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.</description>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
    <other_name>Biomatrix Flex (Biosensors International)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting coronary stent</intervention_name>
    <description>The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus</description>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <other_name>Promus (BSC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
             infarction

          -  Presence of one or more coronary artery stenosis &gt; 50% in a native coronary artery
             with a reference diameter ranging from 2.25 to 4.0 mm which can be covered with one or
             multiple stents

          -  No limitation to the number of treated lesions, number of vessels or lesion length
             according to the randomization group

        Exclusion Criteria:

          -  Known intolerance to aspirin, clopidogrel, heparin, stainless steel, cobalt chromium,
             Biolimus, everolimus, contrast material

          -  Acute ST-segment elevation myocardial infarction

          -  Bypass graft

          -  Inability to provide informed consent

          -  Pregnancy

          -  Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained
             throughout the peri-surgical period

          -  Left ventricular ejection fraction &lt; 25%

          -  Serum creatinine &gt; 180mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Barlis, MBBS PhD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Hospital, Department of Cardiology, Victoria, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, Jüni P, di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010 Jan;31(2):165-76. doi: 10.1093/eurheartj/ehp480. Epub 2009 Nov 4.</citation>
    <PMID>19889649</PMID>
  </reference>
  <reference>
    <citation>Barlis P, van Soest G, Serruys PW, Regar E. Intracoronary optical coherence tomography and the evaluation of stents. Expert Rev Med Devices. 2009 Mar;6(2):157-67. doi: 10.1586/17434440.6.2.157. Review.</citation>
    <PMID>19298163</PMID>
  </reference>
  <reference>
    <citation>Barlis P, Dimopoulos K, Tanigawa J, Dzielicka E, Ferrante G, Del Furia F, Di Mario C. Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. Int J Cardiol. 2010 May 28;141(2):151-6. doi: 10.1016/j.ijcard.2008.11.204. Epub 2009 Jan 19.</citation>
    <PMID>19155076</PMID>
  </reference>
  <reference>
    <citation>Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol. 2009 May 15;134(2):180-8. doi: 10.1016/j.ijcard.2008.05.069. Epub 2008 Sep 4.</citation>
    <PMID>18775576</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>August 2, 2014</last_update_submitted>
  <last_update_submitted_qc>August 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northern Hospital, Australia</investigator_affiliation>
    <investigator_full_name>Dr Peter Barlis</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug-eluting stents</keyword>
  <keyword>Tomography, Optical Coherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Umirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

